ScienceCloses Jul 23

Will the FDA approve Sarclisa SC for multiple myeloma by July 23, 2026?

55%

Stable · last 24h

📊 0 bettors💎 0 at stake

Your stake

💎10

Potential payout

—

🤖 Context

This market will resolve to YES if the FDA approves the subcutaneous formulation of Sarclisa (isatuximab) for the treatment of multiple myeloma by July 23, 2026. It will resolve to NO if the FDA does not approve it by that date.

🔍 Sources

Sources used to create this market

🔗
pharmacally.compharmacally.com
🔗
fda.govfda.gov
🔗
fda.govfda.gov
🔗
fda.govfda.gov
🔗
fda.govfda.gov
🔗
fda.govfda.gov
🔗
fda.govfda.gov
🔗
fda.govfda.gov